Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $21.31M rose 31.8% year over year, ahead of the +15.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at -20.9% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $119.02K (-99.8%) for the fiscal year ending Dec 2026, a slowdown from the -45.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$21.31M-2.8% QoQ
Last fiscal yearDec 2025
$62.89M-45.0% YoY
LTMSep 2026
$74.79M+15.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.8%-99.9%-131.6 pp
1 year-45.0%-99.8%-54.8 pp
3-year CAGR-20.9%+82.1%+103.0 pp
5-year CAGR+90.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
62.89M USD
Year-over-year change
-45.0%
4-year CAGR
+12.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.8% is the 4th highest of 10, against a peer median of +10.2%.
  • Over three fiscal years its annual growth of -20.9% compares with a peer median of +2.4%.
AMLX Competitors
Selling, General & Admin for AMLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M USD+66.3%+37.9%61.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$139.03M USD+19.2%+2.4%3857.6%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$117.61M USD+115.1%-0.3%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$74.79M USD+15.8%-20.9%—
PRTAProthena Corporation plcLTM Mar 2026$54.46M USD-19.1%+6.0%94.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$16.54M USD-15.6%+10.2%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$12.8M USD+10.2%+1.9%—
ACIUAC Immune S.A.LTM Mar 2026CHF 11.38M CHF+4.4%+6.7%307.5%
CLNNClene Inc.LTM Mar 2026$7.9M USD-34.1%-17.0%5897.0%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$7.78M USD+11.4%-90.2%—
Peer median (excluding AMLX) —+10.2%+2.4%307.5%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.